Holen Sie sich die Stockscreener-App
5.58
3.63%
-0.21
Handel nachbörslich:
5.52
-0.06
-1.08%
Schlusskurs vom Vortag:
$5.79
Offen:
$5.52
24-Stunden-Volumen:
33,789
Relative Volume:
1.04
Marktkapitalisierung:
$3.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.06M
KGV:
-0.0789
EPS:
-70.7173
Netto-Cashflow:
$-14.18M
1W Leistung:
-7.62%
1M Leistung:
+2.20%
6M Leistung:
-26.77%
1J Leistung:
-90.68%
1-Tages-Spanne:
$5.50
$5.825
1-Wochen-Bereich:
$5.50
$6.4096
52-Wochen-Spanne:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Firmenname
Cns Pharmaceuticals Inc
Sektor
Branche
Telefon
1-800-946-9185
Adresse
2100 WEST LOOP SOUTH, HOUSTON
Vergleichen Sie CNSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.58 | 3.59M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Eingeleitet | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNS Pharmaceuticals says priority ‘is to transform’ how company operates - TipRanks
CNS Pharmaceuticals’ new CEO outlines strategic overhaul By Investing.com - Investing.com Canada
CNS Pharmaceuticals (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287 - Digital Journal
CNS Pharmaceuticals Announces Strategic Review Focused on Lead Drug Candidate TPI 287 - citybuzz -
CNS Pharmaceuticals (CNSP) CEO Outlines Strategic Vision for Fut - GuruFocus
CNS Pharmaceuticals’ new CEO outlines strategic overhaul - Investing.com
CNS Pharmaceuticals Issues Letter to Shareholders - ACCESS Newswire
New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - Stock Titan
Breakout Move: Is CNS Pharmaceuticals Inc stock good for income investorsMarket Volume Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next? - Defense World
Is CNS Pharmaceuticals Inc. being accumulated by smart money2025 Major Catalysts & Precise Buy Zone Identification - bollywoodhelpline.com
CNS Pharma Stock Up Over 30% - Nasdaq
Weekly Trades: Is CNS Pharmaceuticals Inc in a long term uptrendJuly 2025 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn
How CNS Pharmaceuticals Inc. stock compares to market leadersForecast Cut & AI Optimized Trading Strategy Guides - ulpravda.ru
How CNS Pharmaceuticals Inc. stock reacts to global recession fears2025 Price Targets & Growth Focused Investment Plans - Улправда
How CNS Pharmaceuticals Inc. stock performs after earningsJuly 2025 Summary & Detailed Earnings Play Alerts - Улправда
Should I hold or sell CNS Pharmaceuticals Inc. stock in 2025Earnings Risk Summary & Reliable Volume Spike Alerts - Улправда
Dividend Watch: How CNS Pharmaceuticals Inc. stock performs in rate cut cycles2025 Investor Takeaways & Accurate Trade Setup Notifications - Улправда
CNS Pharmaceuticals shares dip after CEO departure announcement - MSN
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 0.5% – Here’s Why - Defense World
Aug Reactions: How CNS Pharmaceuticals Inc stock performs in rate cut cycles2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn
CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco’s departure - MSN
Whats Driving Tourism Finance Corporation of India Limited Stocks Recent Momentum Key TrendsCandlestick Trading Patterns & High Return Capital Strategies - earlytimes.in
Why CNS Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда
Will CNS Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Is CNS Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Earnings Report & High Conviction Buy Zone Picks - Улправда
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 19, 2025) - GuruFocus
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 18, 2025) - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Announces New CEO Appointment - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO - Digital Journal
CNS Pharmaceuticals Appoints Rami Levin as CEO to Advance Brain Cancer Pipeline - citybuzz -
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns By Investing.com - Investing.com Australia
CNS Pharmaceuticals appoints Rami Levin as CEO effective Jan 1, 2026 - marketscreener.com
CNS Pharmaceuticals stock falls after CEO steps down - Investing.com India
CNS Pharmaceuticals stock falls after CEO steps down By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns - Investing.com
CNS Pharmaceuticals Announces CEO Transition - TradingView — Track All Markets
CNS Pharmaceuticals (CNSP) appoints new CEO Rami Levin and outlines Climaco severance - Stock Titan
CNS Pharmaceuticals (CNSP) Appoints New CEO - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco - Investing.com India
Brain cancer drug developer taps new CEO with global track record - Stock Titan
CNS Pharmaceuticals Earnings Notes - Trefis
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Finanzdaten der Cns Pharmaceuticals Inc-Aktie (CNSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):